Exogene develops an AI platform paired with in-house, high-throughput wet-lab TCR screening to identify rare, natural TCRs for TCR-based cell therapies. The company raised US$2 million to produce core wet‑lab datasets to train and validate its AI and to advance a pilot project with Immunocore. Exogene says its platform can screen billions of TCRs in seconds, addressing scalability limits of current wet‑lab approaches. It plans to partner with pharma and biotech to discover TCRs for therapeutic applications and also to develop its own TCR‑based cell therapies for out‑licensing. Longer term, Exogene aims to expand beyond cancer into larger markets such as immune system rejuvenation by targeting senescent T cells. The company is based at the BioEscalator in Oxford, UK.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2021